INTRODUCTION
Gene amplification, as a mechanism leading to overexpression of proto-oncogenes, plays a major role in cancer development. Numerous oncogenes have been identified and their characterization has led to a better understanding of tumorigenesis (1) . Activated oncogenes are also important prognostic factors (2) . Examples include HER2/neu in breast cancer (3) , MYCN in neuroblastoma (2) and MYCC in small cell lung cancer (4) . In addition, amplified oncogenes are potential molecular targets for cancer treatment, as recently demonstrated for HER2/neu in breast cancer (5) .
Amplification of the MYC-family of proto-oncogenes (MYCC, MYCN and MYCL1) in human lung cancers has been well characterized (6) . MYCC is amplified in both small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC), while MYCN and MYCL1 amplifications are usually limited to SCLC (6) . Although MYC gene amplification is a rare event in primary lung tumors, it is more frequently observed in lung cancer cell lines and primary lung cancer following chemotherapy (4, 7) . Other oncogenes in lung cancer are also amplified at low frequency (8) and include cyclin D1, EGFR, HER2/neu and MDM2 (9) (10) (11) . However, the decoy receptor 3 (DcR3) gene, located on chromosome 20q13 that blocks FAS ligand induced apoptosis, was found to be amplified in eight out of 16 primary lung tumors (12) .
The chromosome 3q26-27 amplicon has recently been identified in non-small cell lung carcinoma by comparative genomic hybridization (CGH) (13, 14) . This amplicon is observed primarily in squamous cell carcinomas (SCC) of the lung and is rarely found in adenocarcinomas (15, 16) . Multiple candidate oncogenes including PIK3CA (14) and amplified in SCC (AIS), map to this region (17) .
Several techniques have been used to identify DNA amplification in cancer, including cytogenetic and/or molecular methods such as comparative genome hybridization (13) and the newly developed CGH on arrayed BAC (14) or cDNA clones (18) . Restriction landmark genomic scanning (RLGS), a twodimensional gel electrophoresis, is a method mainly used for the detection of genome-wide DNA methylation patterns; however, RLGS also has the capacity to perform genome-wide scanning for DNA amplification (19) (20) (21) . Intensities of RLGS fragments correlate precisely with gene copy numbers since RLGS profiles display labeled restriction ends. The increased copy number leads to an enhanced RLGS fragment as compared to the one found in the normal tissue DNA. RLGS has been successfully used for the identification of DNA amplification in a variety of human primary malignancies (21) (22) (23) (24) (25) , human cancer cell lines (26) (27) (28) and mouse tumors (29, 30) .
Here we report a genome scan for amplified sequences in lung cancer by RLGS. Four amplified regions have been identified and characterized in primary lung cancers. Among them, three are known amplicons on 1p34, 6q21 and 3q26-27 and the fourth is on 11q22, a region for which no amplification has been reported in primary lung cancers. Detailed characterization of the 11q22 amplicon allowed us to define the amplified region and identify cIAP1 and cIAP2 as candidate oncogenes in lung cancer.
RESULTS
A genome-wide search for amplified sequences in human lung cancers by RLGS To identify novel regions of DNA amplification in human lung cancers, 20 paired normal tissue and primary NSCLC, nine NSCLC cell lines, five primary SCLC and eight SCLC cell lines were analyzed by RLGS. RLGS profiles of primary lung cancers were compared with a profile derived from normal lung tissue from the same patient. All enhanced RLGS fragments were named according to RLGS master profile addresses previously established (31) . Two types of enhancements were identified in the tumor profiles. The first type was seen in RLGS fragments that were also present in the normal profiles with diploid copy number intensity. For example, the intensity of 5E14 on the normal lung profile of patient (PT) 2 is the same as the intensity of surrounding fragments and represents a single-copy sequence while the intensity of 5E14 is enhanced in the tumor of PT2 (Fig. 1A) . The second type of enhancement in tumor profiles was seen in RLGS fragments that were not present in the normal profile (Fig. 1B) . The first type represents DNA amplification of a single copy sequence, the second type most likely represents hypomethylation of a normally methylated repeat sequences that contains a NotI site or a novel rearrangement (22, 32) .
The enhanced RLGS fragments of the first type identified in at least one patient are listed in Table 1 . Seven out of 20 NSCLC tumors and one of the five SCLC primary tumors showed amplification. RLGS fragments 1G20, 2F51, 3D17, 3D21, 3G68, 5E14 and 5GXX were enhanced in two primary lung cancers, while all other fragments were found only in one tumor. Three NSCLCs (PT1, PT11 and PT14) showed enhancement of only a single RLGS fragment, while the other five tumors (PT2, PT6, PT7, PT12 and PT24) showed multiple enhanced RLGS fragments. RLGS fragments 1G20, 2E46, 2F72, 3E46 3E58, 3D17 and 3D21 were present with low-level enhancement at equal intensity in PT6 (Fig. 1C, showing 2F72 , 3E46, 3E58, 3D17 and 3D21), suggesting that they might be derived from a single amplicon. The tumor from PT24 showed enhancement in a subset of these fragments (1G20, 3D17 and 3D21), suggesting that this tumor may have a smaller amplicon size. In addition, the tumor from PT12 showed several amplified sequences (fragments 2F41/42, 2F50, 3D53, 4D13 and 5C25). However, intensities of these fragments varied, suggesting that they may be derived from different amplicons (data not shown).
Each of the lung cancer cell line profiles were compared with two normal lung profiles. Overall, cell lines showed a higher number of enhancements as compared to primary tumors. Among the 17 cell lines, eight out of the nine NSCLC cell lines and all eight SCLC cell lines showed amplified sequences ( Table 2 ). The majority of fragments showed low-level (3-5-fold) enhancement on RLGS profiles as measured by phosphorimager quantification. Three cell lines, H23, H125 and H82, showed numerous enhanced sequences at low levels, possibly as a result of whole chromosomal gains, or gains of large chromosomal regions. In contrast to the low-level amplifications seen in the majority of the enhanced RLGS fragments, fragments 3B35 and 4C3 were amplified in cell lines H23, H82, N417 and H792 with copy numbers greater than 20. Seven RLGS fragments (2C59, 2F36, 2G55, 3B35, 3G68, 4C3 and 5C1) were enhanced in more than one cell line ( Table 2) .
Taken together our analysis identified 17 enhanced RLGS fragments of the type 1 group in primary lung tumors that most likely represent DNA amplification. The RLGS analysis also confirms previous data (7) and identified a higher degree of amplified sequences in lung cancer cell lines, most likely a reflection the overall trend of increased genomic instability in cancer cell lines.
Cloning of RLGS fragments
To further characterize amplified sequences in lung cancer, it was critical to clone and sequence the enhanced RLGS fragments. Subsequent database searches allowed the mapping of sequences to specific chromosomal regions and the identification of genes in the vicinity. Some of the sequences (3B35, 3E24, 3C71, 3G68 and 4C3) had been identified in previous studies (22, 28) . Fragments 3B35 and 4C3, which are amplified in cell lines H23, H82, N417 (33) and H792, are sequences located in the MYCC gene region on chromosome 8q24 (22) . The finding of MYCC amplification in these lung cancer cell lines confirms previous work (33) .
In order to identify novel amplified sequences in lung cancer additional fragments of the type 1 group, enhanced in primary lung tumors were cloned. The NotI-EcoRV plasmid library and corresponding library mixing gels were used to facilitate the cloning (19) . Table 1 summarizes the information obtained from database searches of the cloned RLGS fragments. Two groups of sequences could be identified from database and literature searches. The first group includes sequences that fell into known regions of DNA amplification in lung cancers. For example, amplified fragments from tumor PT6 are all located on chromosome 3q26-27, a region known to be amplified in SCC of the lung (14) . Fragments 3D17, 3D21 and 1G20 were also amplified in SCC tumor PT24 but 2F72 and 3E58 were not, which indicates that the amplicon in this tumor is smaller than in PT6. Fragments 2F41/42 and 2F50, amplified in PT12, were mapped to chromosome 1p34 $1 Mbp away from the MYCL1 gene. RLGS fragments 4D13 and 5C25, amplified in PT12, are located on chromosome 6q21, a region of amplification in lung cancer, recently identified by CGH (34) . The second group of sequences fell into chromosomal regions for which candidate oncogenes had been identified in other types of cancers, but not in lung cancer. For instance, 5E14 was located on chromosome 11q22, a 1.8 Mbp region that has been reported to be amplified in primary esophageal cancers and cancer cell lines as well as other types of cancer (35) . To our knowledge, this chromosomal region has not been well characterized in lung cancer.
Confirmation of DNA amplification by Southern hybridization
To confirm that the enhanced RLGS loci represent genomic amplification, probes from either RLGS fragments or adjacent sequences were prepared for Southern hybridizations. A probe for insulin promoter factor 1 (IPF1) gene located on chromosome 13q12.1 was used as DNA loading control for all the hybridizations. We confirmed DNA amplification for four chromosomal regions for which RLGS enhancements had been identified. Southern hybridization for the amplicon on chromosomal region 3q26-27, identified in PT6 and PT24, showed approximately a 5-fold (3D17) or 10-fold (2F72) increased intensity in the tumor of PT6 as compared to the normal adjacent tissue ( Fig. 2A) . Southern hybridization using probe 2F41/42 for the second amplicon on chromosome 1p34, showed approximately a 7-fold increase in intensity (Fig. 2B ). This region includes MYCL1, which was amplified approximately 12-fold. Amplification of chromosome 11q22 was demonstrated using cIAP1 as probe for Southern hybridization (see Fig. 2C , and below). We found that the region was amplified approximately 7-fold in PT2, and 5-fold in cell line H2086. The fourth genomic region on 6q21 showed DNA amplification up to 14-fold in PT12 (Fig. 2D ).
This region includes the popeye protein 3 (POP3), blood vessel epicardial substance (BVES), and EST LOC135537 and KIAA1320.
Characterization of the 11q22 amplicon
Among the four amplicons described above, the 1p34, 6q21 and 3q26-27 amplicons are known regions of DNA amplification in lung cancer. The amplicon on 11q22 was also found to be amplified in esophageal cancer within a 1.8 Mbp region (35) . Although a large amplified region from 11q13 to 11qter has been reported in the NSCLC cell line RVH6489 (36), 11q22 had not been reported previously as a clearly defined amplicon in lung cancer. 5E14 is located in an area on 11q22 that has been completely sequenced (Fig. 3) . In order to define the core amplified region, a set of probes (Table 3) were designed for Southern hybridizations (Figs 3 and 4) . The intensity of the Southern hybridization signals was quantified using phophorimager and is listed in Figure 4 . The amplicon in PT2 was localized to a region extending from LOC143867 to MMP1, spanning 1.19 Mbp. The amplicon in cell line H2086 is at least as large as the one detected in PT2 although its exact size could not be determined (Fig. 4 ). PT7 showed low-level amplification of a region localized between markers MMP7 and LOC143868 spanning an interval of 0.92 Mbp and represents the minimal region of overlap. This region includes cIAP1 and cIAP2 as potential candidates oncogenes but not the MMP genes. We performed immunohistochemistry for both genes on nine tumor sections and nine normal sections from the same patients and found overexpression of cIAP1 in five out of nine tumor samples and overexpression of cIAP2 in six out of nine cases (see Fig. 5 for examples and Table 4 ). In this set of nine tissue sections we included the samples from PT2 and PT7, both characterized by amplification of the region containing cIAP1 and cIAP2. Immunohistochemistry showed that cIAP1 was overexpressed only in PT7 but not in PT2 (Fig. 5B) , whereas cIAP2 was found to be overexpressed in both patient samples ( Fig. 5A and B) . Overall cIAP2 seemed to be expressed at a higher degree (six out of nine samples with >10% cells expressing cIAP1) when compared to cIAP1 with only two samples expressing this gene in >10% of the cells. Importantly, we also identified cIAP1 and cIAP2 overexpression in patients with no evidence of genomic amplification (i.e. PT1, 10, 33 and 35 see Table 4 ). We also performed western blot analysis to obtain an independent measure for cIAP1 and cIAP2 overexpression. Seven patient samples (normal and tumor), including PT2 and PT7, were used for western blot analysis. Proteins were hybridized sequentially with cIAP1 and cIAP2 antibodies, with a tubulin antibody as a loading control. The data is shown in Figure 6 and summarized in Table 4 . Samples with amplification (PT2 and PT7) as well as without amplification (PT1), showed an increased expression of both cIAP1 and cIAP2. Patients 32 and 34 showed increased expression of cIAP2 but not cIAP1. The analysis of patient 33 protein was inconclusive due to the poor quality of the isolated protein lysate. This data supports the findings by immunohistochemistry that overexpression of both cIAP1 and cIAP2 occurs in cells with and without DNA amplification, suggesting different mechanisms in these cells that contribute to overexpression.
In addition, Southern hybridization was performed on another 44 non-small cell lung cancers to detect cIAP1 gene amplification. Only a single additional tumor with 2.67-fold amplification was detected (data not shown). Together with the RLGS data this indicates that the amplification of 11q22 in lung cancer is infrequent (three out of 64 tumors tested, or 4.5%), similar to the observation in other types of cancer (35) .
DISCUSSION
In the present study, we have performed restriction landmark genomic scanning to identify DNA amplification in human lung cancer. The characterization of enhanced RLGS fragments in primary lung cancer identified amplicons on 1p34, 3q26-27, 11q22 and 6q21. A more detailed analysis of the amplicons on 11q22 identified the inhibitors of apoptosis 1 and 2 (cIAP1 and cIAP2) as candidate oncogenes in this region of amplification.
Amplification of 1p34 had previously been described and this amplicon contains the MYCL1 oncogene (33) . Amplification of 3q26-27 had been reported in 25-40% of patients with squamous cell carcinoma of the lung (16, 37, 38) , and only very rarely in adenocarcinomas (15, 16) . Consistent with these published reports, we found amplification of 3q26-27 in two out of eight squamous cell carcinomas. The cloned fragments derived from this amplicon are located in an area extending 30 Mbp, including several candidate oncogenes in lung cancers (14, 39, 40) . For example, PIK3CA, a gene associated with the phosphatidylinositol-3-kinase pathway, is a candidate oncogene in both lung cancer (14) and cervical cancer (41) . Amplification of 3q26-27 has been found in a variety of human cancers, including head and neck squamous cell carcinoma (42, 43) , cervical cancer (41), primary carcinoma of the fallopian tube (44), osteosarcomas (45), ovarian cancer (46, 47) , and nasopharyngeal carcinoma (48) . In head and neck squamous cell carcinomas and in ovarian carcinomas, amplification correlates with tumor progression (42) .
Amplification of 6q21, found in SCLC, has also been described in breast cancer (49, 50) . This amplicon is currently not well defined but includes the known genes prolyl endopeptidase (PREP), blood vessel epicardial substance (BVES) and POP3. PREP is an enzyme involved in the maturation and degradation of peptide hormones and neuropeptides, and displays increased activity in human lung tumors compared to normal lung (51) . BVES and POP3 are expressed in heart and skeletal muscle and are essential for coronary vasculogenesis (52) . However, currently no candidate oncogene has been characterized. To our knowledge amplification of 11q22 had only been described in a NSCLC cell line, RVH6489, extending from 11q13 to 11qter (36) . This indicates that DNA amplification of this sequence is a rare event. We have found amplified 11q22 sequences in two of 20 tumors by RLGS, however when we tested 44 additional samples by Southern blot analysis we did find amplification in one primary lung cancer, supporting the notion that DNA amplification of 11q22 is a rare event in lung Figure 3 . Known genes and ESTs on chromosome 11q22. The black bar indicates the core amplified region in human primary lung cancer. The region has been completely sequenced (contig NT_009151.8). Genes or ESTs marked in bold were used as probes (Table 3) for Southern hybridization. Gene or EST location in the sequence contig is not drawn to scale. Numbers correspond to location of nucleotides within the NT-009151.8 contig. cancer and thus has been missed in previous studies. The amplicon was previously described in esophageal squamous cell carcinoma cell lines KYSE2270 and KYSE170 and primary tumors (35) . The authors described amplification in BACs RP11-21G19 to 23P6. Based on the current human sequences in this region (NT_009151.8), this 1.1 Mbp region is approximately located between LOC160122 and MMP13 (see also Fig. 3) . Therefore, the region that we identified in PT2 is overlapping with the amplicon in esophageal squamous cell carcinoma. Several lines of evidence support the hypothesis that cIAP1 and cIAP2 are strong candidate oncogenes in this region. First, both genes are localized in the core amplified region defined by two patient samples and one lung cancer cell line. Furthermore, both genes are located in the core-amplified region in esophageal cancers. Second, cIAP1 and cIAP2 are genes that promote cell survival after apoptoic stimuli and thus support tumor growth. The way they achieve the antiapoptotic activity is by the inhibition of specific caspases (53) . Both cIAP1 and cIAP2 prevent the proteolytic processing of pro-caspases -3, -6 and -7 by inhibiting the cytochrome c induced activation of pro-caspase-9 (54). Third, we showed by immunohistochemistry and western blot analysis that both genes are overexpressed at high frequencies in lung cancers. Overexpression is not only seen in tumor samples that do have additional copies of the genes but also in tumors that show no DNA amplification. This indicates that these genes are overexpressed in tumor cells by independent mechanisms. It is currently unclear what these mechanisms are, but they probably function either at the transcriptional or posttranslational level. Fourth, it is interesting to note that recently the inactivation of the apoptosis protease activating factor-1 (APAF1) was described in metastatic melanomas (55) . APAF1 binds to cytochrome c and this complex promotes the activation of caspase-9. Inactivation of APAF1 thus represents an alternative way of preventing cell death and shows the importance of this pathway in normal cell development. It needs to be determined if this alternative way of disrupting the apoptotic pathway is used in lung cancers. Fifth, based on expression studies as well as functional analysis, cIAP1 has been proposed as candidate oncogene in the 11q22 amplicon in esophageal squamous cell carcinoma (35) . Ectopic expression of cIAP1 in mammalian Figure 4 . 11q22 amplicon definition by Southern hybridization. All hybridizations were carried out on the same Southern blot with EcoRI digestions using probes described in Table 3 . The degree of amplification was calculated by densitometry as described in the Materials and Methods. The shaded area indicates sequences that were enhanced 1.5-fold or higher. cells inhibited apoptosis induced by serum deprivation (56) . It was also shown that expression of cIAP1 resulted in the resistance of apoptosis induced by chemotherapeutic agents (35) , and correlated with radiation resistance in cervical cancer (57) . In addition, cIAP2 was overexpressed in human malignant pleural mesothelioma and the high expression of cIAP2 correlated with drug resistance in cancer cells (58) .
In conclusion, and based on our current understanding of cIAP1 and cIAP2, as well as our finding of overexpression, both cIAP genes are strong candidate oncogenes in lung cancer.
MATERIALS AND METHODS

Primary lung cancer tissue samples and cell lines
Primary human lung cancer and normal adjacent tissue samples were collected through the Cooperative Human Tissue Network at The Ohio State University, James Cancer Hospital. A total of 20 NSCLCs were studied, 16 of them had previously been used 
Bold indicates samples with high expression in over 10% of the cells as graded 2 and 3. PT2 and PT7 showed DNA amplification, at low (þ) or high degree (þþ). (2þ) with a cytoplasmic pattern of staining in a large cell carcinoma and absent staining for cIAP2 in the matching normal lung. Negative immunoreactivity for cIAP1 in the same case with absent staining for cIAP1 in the matching normal lung. (B) PT7: strong immunoreactivity for cIAP2 (3þ) with a cytoplasmic pattern of staining in a squamous cell carcinoma and weak to absent (0/1þ) staining for cIAP2 in the matching normal lung. Moderate immunoreactivity for cIAP1 (2þ) with a cytoplasmic pattern of staining in the same case absent staining for cIAP1 in the matching normal lung. (C) PT33: strong immunoreactivity for cIAP2 (3þ) with a cytoplasmic and nuclear pattern of staining in the neoplastic cells and (B) absent staining for cIAP2 in the matching normal lung. Weak immunoreactivity for cIAP1 (1þ) with a cytoplasmic pattern of staining in the same case with absent staining for cIAP1 in the matching normal lung. for DNA methylation profiling (59) . These tumors included eight squamous cell carcinomas, six adenocarcinomas, four large cell carcinomas and two uncharacterized NSCLC. In addition, five SCLCs were obtained from the Mayo Clinic (Rochester, MN, USA). Tissue specimens were procured with IRB approval. Nine non-small cell lung cancer cell lines, H23, H125, H522, H1155, H1299, H2009, H2086, H2172 and A549, and eight SCLC cell lines, H69, H82, H209, H211 H719, H792, H841 and N417, were obtained from ATCC and cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 100 units/ml Penicillin and 0.1 mg/ml Streptomycin (Invitrogen).
Restriction landmark genomic scanning DNA isolation and RLGS was performed according to published protocols (19, 59) . In summary, randomly fragmented ends of high molecular weight DNA were blocked using DNA polymerase I (Boehringer Mannheim), followed by a restriction digestion of the DNA with NotI (Promega, Madison, WI, USA). NotI restriction ends were labeled using [a-
32 P]dGTP and [a-
32 P]dCTP (Perkin Elmer, Foster, CA, USA) in the presence of Sequenase (Amersham, Piscataway, NJ, USA). The DNA was further digested with the restriction enzyme EcoRV (Promega). NotI-EcoRV DNA fragments were separated by molecular weight through an 0.8% agarose gel (first dimension). After an in-gel digestion using the restriction enzyme HinfI (New England Biolabs, Beverly, MA, USA), the second dimension separation was carried out on a 5% polyacryamide gel. The dried gels were exposed to X-ray film for 5-10 days. The RLGS profiles of primary lung tumors and normal adjacent tissue from the same patients were superimposed to detect enhanced RLGS fragments that might represent amplified DNA. The RLGS profiles were exposed to a phosphorimager screen for quantification. All the RLGS fragments were named according to the master profile (see online: http://pandora.med.ohio-state.edu/masterRLGS). Fragments not present in the master profile were named according to the section in which they were found (e.g. 5GXX).
RLGS fragment cloning and sequencing
Clones corresponding to RLGS fragments were identified using the NotI-EcoRV plasmid library and library RLGS mixing gels as previously described (19) . Confirmed plasmid clones were sequenced in the Core Facility of the Division of Human Cancer Genetics using M13 forward primer. The NCBI database, www.ncbi.nlm.nih.gov/, and UCSC human genome project working draft database, http://genome.ucsc.edu/, were searched for sequence homologies and chromosomal locations.
Southern hybridization
Probes were made from either restriction enzyme digested fragments of the plasmid clones or from PCR products. The IPF1 probe was a 493 bp XbaI-EcoRV fragment; the 5E14 probe was a XbaI-EcoRV fragment of 1426 bp; the 2F72 was a 381 bp PstI-BamH1 fragment; and the 2F41/42 probe was a 278 bp BglII-NotI fragment. All other probes were made by PCR amplification of genomic DNA with primers and conditions listed in Table 3 . One microliter of the PCR product was used as template for a second round of PCR amplification. PCR product was purified in an agarose gel and eluted using QIAquick 1 gel extraction kit (Qiagen, Valencia, CA, USA). All the probes were labeled with [a-32 P]dCTP using Prime-It 1 II Random Primer labeling kit (Stratagene). Southern hybridization followed the published protocol (19) . The Southern blots were exposed to phosphorimager screen and quantified.
Immunohistochemical staining
Immunoperoxidase staining was performed on frozen tissue cut at 4 mm intervals and placed on positively charged slides. Slides with specimens were fixed in acetone for 6 min and stored frozen until ready for use. Slides were then rewarmed to room temperature and rehydrated with PBS for 6 min. All slides were quenched for 5 min in a 3% hydrogen peroxide solution in water to block for endogenous peroxidase prior to immunostaining and then rinsed in tap water. No antigen retrieval was performed. The primary antibodies used were cIAP1 (clone H-83, Santa Cruz, CA, USA), no.SC-7943, 1:50) and cIAP2 (clone H-85, Santa Cruz, CA, USA), no.SC-7944, 1:50). Slides were then placed on a Dako Autostainer and incubated for 60 min at room temperature with the specific primary antibodies for cIAP1 or cIAP2. The detection system used was a labeled streptavidin-biotin complex. This method is based on the consecutive application of (1) a primary antibody against the antigen to be localized, (2) biotinylated linking antibody, (3) enzyme conjugated streptavidin, and (4) substrate chromogen (DAB). Slides were then counterstained in Richard Allen hematoxylin, dehydrated through graded ethanol solutions and coverslipped. Negative controls for both cIAP1 and cIAP2 were done by the same procedure as listed above with the omission of the primary antibody. The slides were examined by a pathologist (C.M.) and reviewed with the primary investigators (Z.D., C.P.) with immunoreactivity defined as more than 1% of cells staining. For both cIAP1 and cIAP2 positive results were interpreted as a granular cytoplasmic or nuclear pattern of immunoreactivity. The immunohistochemical staining was graded and recorded as 1þ (1-10% positive cells), 2þ (10-50% positive cells), or 3þ (>50% positive cells). Negative controls were stained appropriately.
Western blot analysis
Human lung samples were crushed in lysis buffer [50 mM TrisHCl, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 0.1% Igepal CA-630, with protease and phosphatase inhibitor cocktails (Sigma)]. Equal amounts of protein (50 mg) were separated on 7.5% SDS-PAGE and transferred onto Hybond C for 1-2 h. After the same wash for primary antibody, proteins were detected using a chemiluminescent detection system (Amersham Pharmacia Biotech).
